Abstract: An object of the present invention is to provide a method capable of detecting whether a subject has systemic lupus erythematosus (preferably nephrotic syndrome) with high accuracy without performing a renal biopsy, a biomarker for carrying out such detection, and the like. The concentration of 3?,4?-didehydro-3?-deoxycytidine in urine collected from a test subject is measured, and this concentration is compared with a reference concentration for control, which allows to detect whether the above-mentioned test subject has systemic lupus erythematosus (preferably lupus nephritis) with high accuracy.

Abstract: Salivary biomarker characterized as low-molecular-weight compounds named metabolites or combinations of these biomarkers are used for detecting cancers. The salivary biomarker for cancer can be, for example, a combination of creatinine, N1-acetylspermidine, ?-aminoadipic acid, N-acetylneuraminic acid, and 1,3-diaminopropane. Due to this configuration, the early detection of pancreatic cancer, breast cancer, oral cancer, and the like is possible in a healthy subject even with saliva having large concentration fluctuations.

Abstract: Processing a capillary distal end into acute-angle, an electrophoretic liquid passing hole through which electrophoretic liquid pass is opened in a flexible insulating plate. An electrodialysis-membrane is bonded covering the electrophoretic liquid passing hole; the capillary is securely bonded to the insulating plate portion with no gap therebetween, the portion excluding electrophoretic liquid passing hole on the electrodialysis top-membrane. A crack forms at the capillary portion at the electrophoretic liquid passing hole, with the capillary entirely secured to the insulating plate except portion at the electrophoretic liquid passing hole. The capillary is securely bonded to the insulating plate; reservoir stores electrophoretic liquid on the insulating plate-side to which the capillary is unsecured. An electrode insertion hole into which an electrode is inserted opened in the reservoir upper portion; the electrode is securely inserted into the electrode insertion hole.

Abstract: Processing a capillary distal end into acute-angle, an electrophoretic liquid passing hole through which electrophoretic liquid pass is opened in a flexible insulating plate. An electrodialysis-membrane is bonded covering the electrophoretic liquid passing hole; the capillary is securely bonded to the insulating plate portion with no gap therebetween, the portion excluding electrophoretic liquid passing hole on the electrodialysis top-membrane. A crack forms at the capillary portion at the electrophoretic liquid passing hole, with the capillary entirely secured to the insulating plate except portion at the electrophoretic liquid passing hole. The capillary is securely bonded to the insulating plate; reservoir stores electrophoretic liquid on the insulating plate-side to which the capillary is unsecured. An electrode insertion hole into which an electrode is inserted opened in the reservoir upper portion; the electrode is securely inserted into the electrode insertion hole.

Abstract: Salivary biomarker characterized as low-molecular-weight compounds named metabolites or combinations of these biomarkers are used for detecting cancers. The salivary biomarker for cancer can be, for example, a combination of creatinine, N1-acetylspermidine, ?-aminoadipic acid, N-acetylneuraminic acid, and 1,3-diaminopropane. Due to this configuration, the early detection of pancreatic cancer, breast cancer, oral cancer, and the like is possible in a healthy subject even with saliva having large concentration fluctuations.

Abstract: The present invention relates to a method for diagnosing, and treating renal disease in a patient by having a test performed for detecting or quantifying one or more renal disease markers present in a test blood sample from the patient; and administering treatment to improve renal function. In particular embodiments, the test performed quantifies cis-aconitate, and the patient is identified as having the renal disease when a concentration of cis-aconitate present in the patient's test blood sample is higher than that of a control. Methods of the present invention can allow diagnosis and treatment of patients with early stage renal disease, such as early stage renal failure. Another aspect of the present invention relates to methods for screening for a prophylactic/therapeutic agent for treating renal disease using one or more renal disease markers.

Abstract: A normal person (i.e. a control) and liver diseases such as drug induced liver injury, an asymptomatic hepatitis B carrier, an asymptomatic hepatitis C carrier, chronic hepatitis B, chronic hepatitis C, liver cancer, a nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and simple steatosis (SS) are identified by measuring the concentrations of ?-Glu-X (X represents an amino acid or an amine) peptides or the levels of AST or ALT in blood and carrying out, for example, a multiple logistic regression based on the measured value.

Abstract: Ratios of measured values of glucose, citrate, and cis-aconitate in a biological sample obtained from a subject to measured values of glucose, citrate, and cis-aconitate in a biological sample obtained from a healthy subject are calculated, and the glucose ratio, the citrate ratio, and the cis-aconitate ratio are used to evaluate and/or assess fatigue. Similarly, an isocitrate ratio, a succinate ratio, a malate ratio, and a lactate ratio are calculated, and these ratios are used together with the three ratios to evaluate and/or assess fatigue. This makes it possible to objectively and easily diagnose and evaluate fatigue.

Abstract: Disclosed is a method for promptly identifying a liver disease. A normal person or a liver disease such as drug-induced liver injury, asymptomatic hepatitis B carrier, chronic hepatitis B, hepatitis C with persistently normal ALT, chronic hepatitis C, cirrhosis type C, hepatocellular carcinoma, simple steatosis, or non-alcoholic steatohepatitis is identified by measuring the concentration of a ?-Glu-X (wherein X represents an amino acid or an amine) peptide or the level of AST or ALT in blood and carrying out, for example, a multiple logistic regression based on the measured value.

Abstract: Provided is a biomarker that enables easy and rapid detection of oxidative stress on a living organism and enables prevention of tissue damage or cell necrosis by drug administration, and which is a powerful marker for the study of toxicity and pharmacokinetics of various agents. Oxidative stress is determined by measuring blood concentration of ophthalmic acid, which is a substance that varies in blood depending on the variation of reduced glutathione (GSH) concentration in a biological sample with the use of an analyzer such as a capillary electrophoresis-mass spectrometer. Further, an anti-oxidative stress agent is screened by administering an anti-oxidative stress candidate agent to a non-human animal under oxidative stress conditions, measuring blood concentration of ophthalmic acid, and evaluating the degree of decrease in the ophthalmic acid concentration.

Abstract: An object of the present invention is to provide a method for accurately determining even a renal disease that could not have been detected by various conventional renal disease test methods with a reduced burden on a subject (a donor of a test sample). Another object of the present invention is to provide a method capable of determining an early stage renal disease, focusing on a renal disease marker substance with a small blind GFR area. Further, another object of the present invention is to provide a novel method for screening for a prophylactic/therapeutic agent for a renal disease capable of efficiently screening for a novel prophylactic/therapeutic agent for a renal disease that focused on a new, previously unnoticed renal disease marker substance. In order to achieve these objects, the present invention employs the step of detecting or quantifying one or two or more renal disease marker substances present in a test blood sample.

Abstract: Provided is a biomarker that enables easy and rapid detection of oxidative stress on a living organism and enables prevention of tissue damage or cell necrosis by drug administration, and which is a powerful marker for the study of toxicity and pharmacokinetics of various agents. Oxidative stress is determined by measuring blood concentration of ophthalmic acid, which is a substance that varies in blood depending on the variation of reduced glutathione (GSH) concentration in a biological sample with the use of an analyzer such as a capillary electrophoresis-mass spectrometer. Further, an anti-oxidative stress agent is screened by administering an anti-oxidative stress candidate agent to a non-human animal under oxidative stress conditions, measuring blood concentration of ophthalmic acid, and evaluating the degree of decrease in the ophthalmic acid concentration.

Abstract: A normal person (i.e. a control) and liver diseases such as drug induced liver injury, an asymptomatic hepatitis B carrier, an asymptomatic hepatitis C carrier, chronic hepatitis B, chronic hepatitis C, liver cancer, a nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and simple steatosis (SS) are identified by measuring the concentrations of ?-Glu-X (X represents an amino acid or an amine) peptides or the levels of AST or ALT in blood and carrying out, for example, a multiple logistic regression based on the measured value.

Abstract: Provided is a biomarker that enables easy and rapid detection of oxidative stress on a living organism and enables prevention of tissue damage or cell necrosis by drug administration, and which is a powerful marker for the study of toxicity and pharmacokinetics of various agents. Oxidative stress is determined by measuring blood concentration of ophthalmic acid, which is a substance that varies in blood depending on the variation of reduced glutathione (GSH) concentration in a biological sample with the use of an analyzer such as a capillary electrophoresis-mass spectrometer. Further, an anti-oxidative stress agent is screened by administering an anti-oxidative stress candidate agent to a non-human animal under oxidative stress conditions, measuring blood concentration of ophthalmic acid, and evaluating the degree of decrease in the ophthalmic acid concentration.

Abstract: The present invention provides a novel oral cancer and periodontal disease salivary metabolome for use in the diagnosis or for providing a prognosis for oral cancer and periodontal disease in an individual. The present invention also provides novel methods of diagnosing or providing a prognosis for oral cancer or periodontal disease by detecting metabolites found in the saliva of an individual. Finally, the present invention provides kits for the detection of salivary metabolites useful in the diagnosis or prognosis of oral cancer and periodontal disease in an individual.

Abstract: In a mass spectrometry system designed so as to feed a solution to an interface 20 between a separation analysis instrument (10) and amass spectrometer 50, an internal standard for mass calibration is mixed with the solution (an electrophoresis buffer solution 16 of capillary electrophoresis apparatus 10, a mobile phase of liquid chromatograph or a sheath solution for obtaining an electrical contact of the separation analysis instrument with the mass spectrometer), and a detected mass is calibrated. Thereby, it is possible to simply and conveniently calibrate the mass of a substance to be measured without using a calibration spray device or employing a post column introduction method.

Abstract: Provided is a biomarker that enables easy and rapid detection of oxidative stress on a living organism and enables prevention of tissue damage or cell necrosis by drug administration, and which is a powerful marker for the study of toxicity and pharmacokinetics of various agents. Oxidative stress is determined by measuring blood concentration of ophthalmic acid, which is a substance that varies in blood depending on the variation of reduced glutathione (GSH) concentration in a biological sample with the use of an analyzer such as a capillary electrophoresis-mass spectrometer. Further, an anti-oxidative stress agent is screened by administering an anti-oxidative stress candidate agent to a non-human animal under oxidative stress conditions, measuring blood concentration of ophthalmic acid, and evaluating the degree of decrease in the ophthalmic acid concentration.

Abstract: When the migration time of a low molecular weight compound having an unknown migration time in microchip electrophoresis, capillary electrophoresis, or a capillary electrophoresis mass spectrometer is predicted, first, with respect to a substance having a known electrophoretic migration time, characteristic quantities (descriptors) thereof which can be numerically expressed from a structure thereof are computed to predict the relation between the characteristic quantities (descriptors) and the migration time; the migration times of some substances are measured by electrophoresis or an electrophoresis mass spectrometer to learn about the relation; and using the learnt result, the migration time of the substance having an unknown migration time in the electrophoresis or electrophoresis mass spectrometer is predicted from the structure thereof.

Abstract: [Problems to be Solved] An objective of the present invention is to provide methods and kits for identifying the function of a functionally unknown gene product, and methods and kits for identifying a binding substance, which are widely applicable to numerous organism species. [Means to Solve the Problems] At least one gene product is added to a compound cocktail such as a metabolic compound cocktail containing all of the metabolic substances, coenzymes, and such involved in a certain metabolic system, the mixture is reacted, and then a change occurred in the compound cocktail is detected, thereby making it possible to identify the function of the gene product or a substance that binds thereto.